[go: up one dir, main page]

WO2003028723A1 - Compositions pharmaceutiques destinee a l'absorption par voie percutanee contenant des derives d'imidazopyridine fondus - Google Patents

Compositions pharmaceutiques destinee a l'absorption par voie percutanee contenant des derives d'imidazopyridine fondus Download PDF

Info

Publication number
WO2003028723A1
WO2003028723A1 PCT/JP2002/010031 JP0210031W WO03028723A1 WO 2003028723 A1 WO2003028723 A1 WO 2003028723A1 JP 0210031 W JP0210031 W JP 0210031W WO 03028723 A1 WO03028723 A1 WO 03028723A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
percutaneous absorption
pharmaceutical compositions
containing fused
imidazopyridine derivatives
Prior art date
Application number
PCT/JP2002/010031
Other languages
English (en)
Japanese (ja)
Inventor
Hiroko Matsumura
Hiroko Kato
Eiichi Mafune
Original Assignee
Saitama Daiichi Pharmaceutical Co., Ltd.
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saitama Daiichi Pharmaceutical Co., Ltd., Shionogi & Co., Ltd. filed Critical Saitama Daiichi Pharmaceutical Co., Ltd.
Priority to JP2003532055A priority Critical patent/JPWO2003028723A1/ja
Publication of WO2003028723A1 publication Critical patent/WO2003028723A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique destinée à l'absorption par voie percutanée. Ladite composition comprend (a) un dérivé d'imidazopyridine fondu représenté par la formule générale (I) et (b) un acide gras présentant de 8 à 12 atomes de carbone tels qu'un acide undécylénique, un acide valproïque, un acide caprique ou un acide laurique et présente d'excellentes propriétés d'absorbabilité des principes actifs. Dans ladite formule (I), R représente aryle ou un groupe hétérocyclique aromatique ; et A représente un groupe alicyclique présentant de 5 à 9 éléments qui peut contenir un ou plusieurs éléments sélectionnés parmi O, S, SO, SO2, et NR1 (où R1 représente hydrogène, alkyle, carboxyle estérifié, carbamoyle ou acyle) et peut être substitué par alkyle.
PCT/JP2002/010031 2001-09-27 2002-09-27 Compositions pharmaceutiques destinee a l'absorption par voie percutanee contenant des derives d'imidazopyridine fondus WO2003028723A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003532055A JPWO2003028723A1 (ja) 2001-09-27 2002-09-27 縮合イミダゾピリジン誘導体を含む経皮吸収用医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001/296798 2001-09-27
JP2001296798 2001-09-27

Publications (1)

Publication Number Publication Date
WO2003028723A1 true WO2003028723A1 (fr) 2003-04-10

Family

ID=19117973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010031 WO2003028723A1 (fr) 2001-09-27 2002-09-27 Compositions pharmaceutiques destinee a l'absorption par voie percutanee contenant des derives d'imidazopyridine fondus

Country Status (2)

Country Link
JP (1) JPWO2003028723A1 (fr)
WO (1) WO2003028723A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788063A (en) * 1984-08-14 1988-11-29 State Of Israel, Represented By Prime Minister's Office Israel Institute For Biological Research Drug delivery system
JPH0482829A (ja) * 1990-07-20 1992-03-16 Sekisui Chem Co Ltd 粘着外用剤
JPH05946A (ja) * 1991-06-27 1993-01-08 Nichiban Co Ltd ケトチフエン含有経皮吸収製剤
EP0556008A1 (fr) * 1992-02-12 1993-08-18 Shionogi & Co., Ltd. Dérivés d'imidazopyridine condensés à activité psychotropique
JP2000026282A (ja) * 1998-07-14 2000-01-25 Shionogi & Co Ltd 溶出性が改善された硬ゼラチンカプセル剤
WO2000053226A1 (fr) * 1999-03-11 2000-09-14 Saitama Daiichi Pharmaceutical Co., Ltd. Compositions facilitant l'absorption cutanee
EP1132094A1 (fr) * 1998-11-17 2001-09-12 Shionogi & Co., Ltd. Preparations administrables par voie percutanee d'activateurs des fonctions cerebrales

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788063A (en) * 1984-08-14 1988-11-29 State Of Israel, Represented By Prime Minister's Office Israel Institute For Biological Research Drug delivery system
JPH0482829A (ja) * 1990-07-20 1992-03-16 Sekisui Chem Co Ltd 粘着外用剤
JPH05946A (ja) * 1991-06-27 1993-01-08 Nichiban Co Ltd ケトチフエン含有経皮吸収製剤
EP0556008A1 (fr) * 1992-02-12 1993-08-18 Shionogi & Co., Ltd. Dérivés d'imidazopyridine condensés à activité psychotropique
JP2000026282A (ja) * 1998-07-14 2000-01-25 Shionogi & Co Ltd 溶出性が改善された硬ゼラチンカプセル剤
EP1132094A1 (fr) * 1998-11-17 2001-09-12 Shionogi & Co., Ltd. Preparations administrables par voie percutanee d'activateurs des fonctions cerebrales
WO2000053226A1 (fr) * 1999-03-11 2000-09-14 Saitama Daiichi Pharmaceutical Co., Ltd. Compositions facilitant l'absorption cutanee

Also Published As

Publication number Publication date
JPWO2003028723A1 (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
IL109526A0 (en) Benzofuranyl- and thiophenyl-alkanecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
ATE132150T1 (de) 3-alkenyl-1-azabicyclo(3.2.0)hept-2-en-2- carbonsäure-verbindungen
ATE107306T1 (de) 3-pyrrolidinylthio-1-azabicyclo (3.2.0)hept-2-en- 2-carbonsäure-verbindungen.
DE68917023D1 (de) 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-en-2-carbonsäureverbindungen.
DE59401923D1 (de) Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NO940523L (no) Nye pyrazin-derivater
KR950008468A (ko) 방향족 카복실산 유도체
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them
WO2002007677A3 (fr) Utilisation de derives d'acide valproique et d'amides d'acide 2-valproenique pour le traitement de la manie en cas de desordre bipolaire
KR970010764A (ko) 크로몬 유도체, 그의 제조방법 및 의약 조성물
AU558261B2 (en) Dialkylaminoalkyoxybenzylalcohol derivatives
WO2003028723A1 (fr) Compositions pharmaceutiques destinee a l'absorption par voie percutanee contenant des derives d'imidazopyridine fondus
EP1174421A4 (fr) Derives de 3-amidinobenzenesulfonamide, compositions medicales qui les contiennent, et produits intermediaires pour leur elaboration
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
PT75385A (en) Process for the preparation of aminoglycosides derivatives and of compositions containing these derivatives
AU3595689A (en) Anthracycline derivatives having cytostatic activity
KR960004341A (ko) 치환1-(7-클로로 퀴놀린-4-일) 피라졸-3- 카르복스아미드 n-옥시드 유도체, 그의 제조 방법 및 그를 함유하는 약학적 조성물
HU901631D0 (en) Process for the preparation of thienyl-piperazine derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: EXCEPT/SAUF OM, TN, VC, ZM, AP (ZM)

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003532055

Country of ref document: JP

122 Ep: pct application non-entry in european phase